HIGHLIGHTS
SUMMARY
The presence of CKD often intervenes in the decision to initiate and maintain life-saving HF therapies among T2DM patients with HF. There is numerous evidence that overweight/obese/T2DM patients had lower adropin levels than healthy volunteers and that a decreased adropin level was associated with a risk of renal dysfunction in patients with T2DM. Although low levels of adropin predicted CKD in T2DM and high levels of adropin were associated with HF, there is no certain evidence that adropin has a discriminative value for CKD in HF patients with T2DM. The results . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.